Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases

 Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases

Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases

Shots:

  • Anima to receive ~ $120M up front, preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under the collaboration
  • Takeda gets an exclusive right to develop and commercialize the mRNA transational modulators and has a time limited option to expands the collaboration for three additional targets for which Anima will receive additional payments including ~$1.2B as milestones and royalties
  • Anima will leverage its translation control therapeutics platform to discover novel mRNA translation modulators against the collaboration targets

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: GlobeNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post